For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Hyderabad-based Gland Pharma reported a 50 per cent increase in its consolidated net profit year-on-year (Y-o-Y), reaching ...

Welcome to Contract Pharma’s annual ranking of the Top 20 Pharma and Biopharma Companies, based on fiscal year 2024 ...

Former X CEO Linda Yaccarino has been named CEO of eMed Population Health, a health company that says it provides a “digital health platform for GLP-1/GIP population health management.” This refers to ...

Investors must now underwrite opportunities with a “financing risk first” mindset, says Siddhi Capital cofounder Steven Finn.

Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and ...

The post, at the company that focuses on care for GLP-1 users, comes after Yaccarino left Elon Musk's X in July.

Former X CEO Linda Yaccarino has taken the helm at eMed Population Health, marking a bold shift from social media to digital healthcare leadership amid rising demand for weight-loss drugs and ...

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve ...

Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

Hims & Hers Health, Inc.'s core growth and product diversification signal long-term potential, despite short-term dips. Click ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...